P-191: Beneficial haemodynamic and endothelial effects of modified-release doxazosin in the combined therapy of moderate-severe hypertension not controlled with monotherapy

Introduction: Modified-release doxazosin (DOX-GITS) is a new therapeutic form which improves the tolerance of simple doxazosin, thus allowing its safe and effective use in combined therapy. Antioxidant and stabilizing effects on endothelial function have been described in animal experiments which are independent of its hypotensive effects. The evaluation in plasma of endothelium-derived peptides such as PAI-1 and the measurement of oxidative stress allow an accurate study of endothelial function. Aims: 1) Evaluation of the medium-term hypotensive effect of the DOX-GITS combination in a moderate-severe hypertensive patient population inadequately controlled with monotherapy. 2) Quantification of impact at endothelial level as evaluated by endothelial peptides and oxidative stress. Patients and Methods: Study Population: n= 10 patients with moderate-severe hypertension (WHO criteria): 6 males, 4 females, with mean age 64 +/− 10 years (48–84), 4 patients with Type 2 diabetes, 4 with dyslipemia (LDL> 160mg/dL), 3 active smokers. Protocol applied pre- and post-treatment (3–6 months) Holter Blood Pressure Monitor: Spacelabs 90207 model. PAI-1 (Menarini ELISA). Normal values: < 50ng /ml. Oxidative Stress: Oxystat (uM/L) Therapeutic Compliance: Hermes Test. Results: Addition of DOX-GITS to treatment produces the following effects: 1) Improvement in BP parameters: a) Average 24 hr Diastolic BP (83.6 +/− 9.8 vs 77 +/− 8.4; p